These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 35258374)

  • 1. Retrospective Evaluation of Treatment Response in Patients with Nonmetastatic Pancreatic Cancer Using CT and CA 19-9.
    Kim SS; Lee S; Lee HS; Bang S; Han K; Park MS
    Radiology; 2022 Jun; 303(3):548-556. PubMed ID: 35258374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Borderline Resectable and Locally Advanced Pancreatic Cancer: FDG PET/MRI and CT Tumor Metrics for Assessment of Pathologic Response to Neoadjuvant Therapy and Prediction of Survival.
    Panda A; Garg I; Truty MJ; Kline TL; Johnson MP; Ehman EC; Suman G; Anaam DA; Kemp BJ; Johnson GB; Halfdanarson TR; Venkatesh SK; Fidler JL; Goenka AH
    AJR Am J Roentgenol; 2021 Sep; 217(3):730-740. PubMed ID: 33084382
    [No Abstract]   [Full Text] [Related]  

  • 3. Early Response Assessment in Pancreatic Ductal Adenocarcinoma Through Integrated PET/MRI.
    Wang ZJ; Behr S; Consunji MV; Yeh BM; Ohliger MA; Gao K; Ko AH; Cinar P; Tempero MA; Collisson EA
    AJR Am J Roentgenol; 2018 Nov; 211(5):1010-1019. PubMed ID: 30063366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perfusion CT to Assess Response to Neoadjuvant Chemotherapy and Radiation Therapy in Pancreatic Ductal Adenocarcinoma: Initial Experience.
    Hamdy A; Ichikawa Y; Toyomasu Y; Nagata M; Nagasawa N; Nomoto Y; Sami H; Sakuma H
    Radiology; 2019 Sep; 292(3):628-635. PubMed ID: 31287389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. (99m)Tc-3PRGD 2 SPECT/CT predicts the outcome of advanced nonsquamous non-small cell lung cancer receiving chemoradiotherapy plus bevacizumab.
    Ma Q; Min K; Wang T; Chen B; Wen Q; Wang F; Ji T; Gao S
    Ann Nucl Med; 2015 Jul; 29(6):519-27. PubMed ID: 25911312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Visual enhancement pattern during the delayed phase of enhanced CT as an independent prognostic factor in stage IV pancreatic ductal adenocarcinoma.
    Fukukura Y; Kumagae Y; Higashi R; Hakamada H; Nagano H; Hidaka S; Kamimura K; Maemura K; Arima S; Yoshiura T
    Pancreatology; 2020 Sep; 20(6):1155-1163. PubMed ID: 32800574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy.
    Amer AM; Zaid M; Chaudhury B; Elganainy D; Lee Y; Wilke CT; Cloyd J; Wang H; Maitra A; Wolff RA; Varadhachary G; Overman MJ; Lee JE; Fleming JB; Tzeng CW; Katz MH; Holliday EB; Krishnan S; Minsky BD; Herman JM; Taniguchi CM; Das P; Crane CH; Le O; Bhosale P; Tamm EP; Koay EJ
    Cancer; 2018 Apr; 124(8):1701-1709. PubMed ID: 29370450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness of
    Yokose T; Kitago M; Matsusaka Y; Masugi Y; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Endo Y; Toyama K; Iwabuchi Y; Takemura R; Ishii R; Nakahara T; Okuda S; Jinzaki M; Kitagawa Y
    Cancer Med; 2020 Jun; 9(12):4059-4068. PubMed ID: 32281301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of Prognostic Radiomic Features From Resectable Pancreatic Ductal Adenocarcinoma in Patients With Advanced Disease Undergoing Chemotherapy.
    Salinas-Miranda E; Khalvati F; Namdar K; Deniffel D; Dong X; Abbas E; Wilson JM; O'Kane GM; Knox J; Gallinger S; Haider MA
    Can Assoc Radiol J; 2021 Nov; 72(4):605-613. PubMed ID: 33151087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimation of Fractional Extracellular Space at CT for Predicting Chemotherapy Response and Survival in Pancreatic Ductal Adenocarcinoma.
    Wang ZJ; Zhang TT; An C; Ko AH; Tempero M; Collisson E; Yeh BM
    AJR Am J Roentgenol; 2020 Sep; 215(3):610-616. PubMed ID: 32755156
    [No Abstract]   [Full Text] [Related]  

  • 11. Assessing local progression after stereotactic body radiation therapy for unresectable pancreatic adenocarcinoma: CT versus PET.
    Toesca DAS; Pollom EL; Poullos PD; Flynt L; Cui Y; Quon A; von Eyben R; Koong AC; Chang DT
    Pract Radiat Oncol; 2017; 7(2):120-125. PubMed ID: 28274396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pancreatic Ductal Adenocarcinoma: Interface Enhancement Gradient Measured on Dual-Energy CT Images Improves Prognostic Evaluation.
    Amer AM; Li Y; Summerlin D; Burgan CM; McNamara MM; Smith AD; Morgan DE
    Radiol Imaging Cancer; 2020 Jul; 2(4):e190074. PubMed ID: 33778722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Female-specific pancreatic cancer survival from CT imaging of visceral fat implicates glutathione metabolism in solid tumors.
    Ballard DH; Nguyen GK; Atagu N; Camps G; Salter A; Jaswal S; Naeem M; Ludwig DR; Mellnick VM; Peterson LR; Hawkins WG; Fields RC; Luo J; Ippolito JE
    Acad Radiol; 2024 Jun; 31(6):2312-2323. PubMed ID: 38129228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of early changes in CT-measured body composition in patients receiving chemotherapy for unresectable pancreatic cancer.
    Salinas-Miranda E; Deniffel D; Dong X; Healy GM; Khalvati F; O'Kane GM; Knox J; Bathe OF; Baracos VE; Gallinger S; Haider MA
    Eur Radiol; 2021 Nov; 31(11):8662-8670. PubMed ID: 33934171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Consolidation chemoradiation (cCTRT) improves survival in responders to first-line chemotherapy (CT) in locally advanced gallbladder cancer (LA-GBC): A new standard of care?
    Alam MN; Agrawal S; Rastogi N; Maria Das KJ
    Indian J Cancer; 2022; 59(4):577-583. PubMed ID: 36861528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pancreatic adenocarcinoma: quantitative CT features are correlated with fibrous stromal fraction and help predict outcome after resection.
    Cai X; Gao F; Qi Y; Lan G; Zhang X; Ji R; Xu Y; Liu C; Shi Y
    Eur Radiol; 2020 Sep; 30(9):5158-5169. PubMed ID: 32346792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-adjuvant chemotherapy CA19-9 levels predict prognosis in patients with pancreatic ductal adenocarcinoma: A retrospective cohort study.
    Imaoka H; Shimizu Y; Senda Y; Natsume S; Mizuno N; Hara K; Hijioka S; Hieda N; Tajika M; Tanaka T; Ishihara M; Niwa Y; Yamao K
    Pancreatology; 2016; 16(4):658-64. PubMed ID: 27178104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CT response of primary tumor and CA19-9 predict resectability of metastasized pancreatic cancer after FOLFIRINOX.
    Tanaka M; Heckler M; Mihaljevic AL; Sun H; Klaiber U; Heger U; Büchler MW; Hackert T
    Eur J Surg Oncol; 2019 Aug; 45(8):1453-1459. PubMed ID: 30981446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Percutaneous Irreversible Electroporation in Locally Advanced and Recurrent Pancreatic Cancer (PANFIRE-2): A Multicenter, Prospective, Single-Arm, Phase II Study.
    Ruarus AH; Vroomen LGPH; Geboers B; van Veldhuisen E; Puijk RS; Nieuwenhuizen S; Besselink MG; Zonderhuis BM; Kazemier G; de Gruijl TD; van Lienden KP; de Vries JJJ; Scheffer HJ; Meijerink MR
    Radiology; 2020 Jan; 294(1):212-220. PubMed ID: 31687922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CT perfusion as a potential biomarker for pancreatic ductal adenocarcinoma during routine staging and restaging.
    O'Malley RB; Cox D; Soloff EV; Zečević M; Green S; Coveler A; Busey JM; Wang CL
    Abdom Radiol (NY); 2022 Nov; 47(11):3770-3781. PubMed ID: 35972550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.